MRD / monitoring · curated MDI catalog

MRD and cancer monitoring molecular tests

MRD and monitoring tests look for molecular evidence of disease over time after diagnosis or treatment. Results depend on assay design, timing, threshold, cancer context and the version that was studied.

34 curated profiles currently match this page. MDI lists them alphabetically and does not rank tests by isolated performance numbers, evidence counts, price or popularity.

  • AlphaLiquid 100 — 118-gene blood-based targeted comprehensive genomic profiling assay for solid tumors.
  • Bladder EpiCheck — Urine DNA methylation test for non-invasive monitoring of bladder cancer recurrence; jurisdiction-specific indications remain separate.
  • CanCatch Custom — Tumor-informed personalized ctDNA MRD approach using WES baseline profiling and patient-specific mutation tracking.
  • CancerDetect — Tissue-informed personalized molecular residual disease and recurrence-monitoring assay for solid tumors.
  • CancerVista — ctDNA liquid-biopsy in-house IVD for MRD detection, recurrence surveillance and therapy monitoring across solid tumors.
  • clonoSEQ — NGS-based clonotype assay for measurable/minimal residual disease assessment in lymphoid malignancies, with disease- and specimen-specific FDA-cleared contexts and additional LDT uses.
  • Cxbladder Monitor — Urine mRNA biomarker test for surveillance and recurrence monitoring in bladder cancer.
  • EasyM — Blood-based multiple myeloma MRD monitoring test using clonotypic peptide mass spectrometry to track M-protein.
  • Foresight CLARITY — Ultra-sensitive ctDNA molecular residual disease assay using PhasED-Seq phased-variant detection, with strong current use in B-cell lymphoma clinical programs.
  • FoundationOne MRD — Tissue-informed ctDNA MRD assay for stage II-III breast cancer using tumor WGS and multiplex dPCR.
  • FoundationOne Tracker — Tissue-informed circulating-tumor-DNA test for treatment-response monitoring in advanced solid tumors.
  • Guardant Reveal — Tissue-free ctDNA MRD/recurrence and therapy-response monitoring test with current methylation-focused commercial lineage.
  • Haystack MRD — Tumor-informed ctDNA molecular residual disease assay for solid tumors using WES-derived personalized panels tracking up to 50 variants.
  • Invitae Personalized Cancer Monitoring — Tumor-informed personalized ctDNA monitoring assay for solid tumors.
  • ipsogen BCR-ABL1 mbcr Kit CE — CE-IVD real-time PCR kit for p190 BCR-ABL1 transcript quantification in B-cell acute lymphoblastic leukemia.
  • ipsogen BCR-ABL1 Mbcr Kit CE — CE-IVD real-time PCR kit for p210 BCR-ABL1 transcript quantification in hematologic malignancies.
  • K-4CARE — Integrated genomic and transcriptomic profiling with ctDNA MRD monitoring for precision oncology.
  • Labcorp Plasma Detect Genome MRD — Tumor-informed whole-genome sequencing ctDNA MRD test currently offered for stage III colon cancer baseline and monitoring.
  • LymphoVista — ctDNA sequencing in-house IVD for lymphoma genotyping, MRD assessment and longitudinal monitoring.
  • MRDVision — Tumor-informed whole-genome MRD assay using a baseline tumor/normal genome and serial blood-based ctDNA monitoring.
  • NavDx — Blood-based TTMV-HPV DNA laboratory-developed test used in HPV-driven cancer management and post-treatment recurrence surveillance.
  • NeXT Personal Dx — Tumor-informed personalized ctDNA LDT using WGS-derived patient-specific signatures for MRD, recurrence and treatment-response monitoring.
  • Northstar Response — Tissue-free methylated-ctDNA liquid biopsy for quantitative treatment-response monitoring across advanced solid tumors.
  • Oncodetect MRD — Tumor-informed ctDNA molecular residual disease test used across solid tumors; current commercial configuration tracks up to 200 tumor-specific variants.
  • Oncuria — Ten-protein urine multiplex immunoassay for bladder-cancer diagnostic, recurrence-monitoring and response-prediction contexts.
  • Precise MRD — Tumor-informed whole-genome sequencing MRD assay tracking up to 1,000 patient-specific variants for treatment and recurrence monitoring.
  • QuantideX qPCR BCR-ABL IS Kit — RT-qPCR BCR-ABL1 monitoring kit standardized to the International Scale for chronic myeloid leukemia treatment-response assessment.
  • RaDaR ST — Personalized tumor-informed ctDNA MRD assay for solid tumors; current ST generation uses WES tumor profiling and tracks up to 48 patient-specific mutations.
  • RadTox — Clinical cfDNA-concentration assay for treatment-response and progression monitoring in solid tumors.
  • Signatera — Personalized tumor-informed circulating tumor DNA molecular residual disease test family. Includes the FDA-authorized Signatera CDx MIBC companion-diagnostic configuration and broader laboratory-developed clinical uses that remain separately scoped.
  • Tempus xM — Tumor-naive liquid-only MRD assay combining methylation- and variant-based workflows for stage II-III colorectal cancer.
  • UroVysion Bladder Cancer Kit — U.S. urine FISH assay used as a diagnostic aid and for recurrence surveillance in bladder cancer.
  • Xpert BCR-ABL Ultra — Automated quantitative molecular test for BCR::ABL1 major-breakpoint transcripts used for chronic myeloid leukemia monitoring.
  • Xpert NPM1 Mutation — Automated RT-qPCR assay for quantitative monitoring of NPM1-mutated acute myeloid leukemia in CE-IVD markets.

How to interpret these records

Clinical purpose comes first. Historical evidence remains attached to the assay version that was actually studied. Evidence counts describe curation coverage, not test quality. Commercial availability is separate from authorization, reimbursement, eligibility and appropriate use.

Find all tests · Understand the evidence · Methodology & provenance